Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) b...
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $8 price t...
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.
Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lo...
ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease...
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.
First chemotherapy-free trial combining ANKTIVA, an IL-15 agonist, natural killer (NK) cell therapy, and Optune immune-stimulat...
